Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S
Many radioactive PSMA inhibitory substances have already been developed for PET diagnostics and therapy of prostate cancer. Because PET radionuclides and instrumentation may not be available, technetium-99 m labelled tracers can be considered as a diagnostic alternative. A suitable tracer is [<su...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/2/577 |
| _version_ | 1827622993365303296 |
|---|---|
| author | Elisabeth Plhak Christopher Pichler Edith Gößnitzer Reingard M. Aigner Herbert Kvaternik |
| author_facet | Elisabeth Plhak Christopher Pichler Edith Gößnitzer Reingard M. Aigner Herbert Kvaternik |
| author_sort | Elisabeth Plhak |
| collection | DOAJ |
| description | Many radioactive PSMA inhibitory substances have already been developed for PET diagnostics and therapy of prostate cancer. Because PET radionuclides and instrumentation may not be available, technetium-99 m labelled tracers can be considered as a diagnostic alternative. A suitable tracer is [<sup>99m</sup>Tc]Tc-PSMA-I&S, primarily developed for radio-guided surgery, which has been identified for diagnostics of prostate cancer. However, there is no commercial kit approved for the preparation of [<sup>99m</sup>Tc]Tc-PSMA-I&S on the market. This work presents an automated process for the synthesis of [<sup>99m</sup>Tc]Tc-PSMA-I&S concerning good manufacturing practice (GMP). We used a Scintomics GRP 4 V module, with the SCC software package for programming sequences for this development. The optimum reaction conditions were evaluated in preliminary experiments. The pH of the reaction solution was found to be crucial for the radiochemical yield and radiochemical purity. The validation of [<sup>99m</sup>Tc]Tc-PSMA-I&S (<i>n</i> = 3) achieved a stable radiochemical yield of 58.7 ± 1.5% and stable radiochemical purities of 93.0 ± 0.3%. The amount of free [<sup>99m</sup>Tc]TcO<sub>4</sub><sup>−</sup> in the solution and reduced hydrolysed [<sup>99m</sup>Tc]TcO<sub>2</sub> was <2%. Our automated preparation of [<sup>99m</sup>Tc]Tc-PSMA-I&S has shown reliability and applicability in the clinical setting. |
| first_indexed | 2024-03-09T11:35:54Z |
| format | Article |
| id | doaj.art-671e7cd51cb24f85aa1dffaac8f4d2d1 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T11:35:54Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-671e7cd51cb24f85aa1dffaac8f4d2d12023-11-30T23:41:47ZengMDPI AGMolecules1420-30492023-01-0128257710.3390/molecules28020577Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&SElisabeth Plhak0Christopher Pichler1Edith Gößnitzer2Reingard M. Aigner3Herbert Kvaternik4Division of Nuclear Medicine, Department of Radiology, Medical University of Graz, Auenbruggerplatz 9, 8036 Graz, AustriaDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1/EG/0122, 8010 Graz, AustriaDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1/EG/0122, 8010 Graz, AustriaDivision of Nuclear Medicine, Department of Radiology, Medical University of Graz, Auenbruggerplatz 9, 8036 Graz, AustriaDivision of Nuclear Medicine, Department of Radiology, Medical University of Graz, Auenbruggerplatz 9, 8036 Graz, AustriaMany radioactive PSMA inhibitory substances have already been developed for PET diagnostics and therapy of prostate cancer. Because PET radionuclides and instrumentation may not be available, technetium-99 m labelled tracers can be considered as a diagnostic alternative. A suitable tracer is [<sup>99m</sup>Tc]Tc-PSMA-I&S, primarily developed for radio-guided surgery, which has been identified for diagnostics of prostate cancer. However, there is no commercial kit approved for the preparation of [<sup>99m</sup>Tc]Tc-PSMA-I&S on the market. This work presents an automated process for the synthesis of [<sup>99m</sup>Tc]Tc-PSMA-I&S concerning good manufacturing practice (GMP). We used a Scintomics GRP 4 V module, with the SCC software package for programming sequences for this development. The optimum reaction conditions were evaluated in preliminary experiments. The pH of the reaction solution was found to be crucial for the radiochemical yield and radiochemical purity. The validation of [<sup>99m</sup>Tc]Tc-PSMA-I&S (<i>n</i> = 3) achieved a stable radiochemical yield of 58.7 ± 1.5% and stable radiochemical purities of 93.0 ± 0.3%. The amount of free [<sup>99m</sup>Tc]TcO<sub>4</sub><sup>−</sup> in the solution and reduced hydrolysed [<sup>99m</sup>Tc]TcO<sub>2</sub> was <2%. Our automated preparation of [<sup>99m</sup>Tc]Tc-PSMA-I&S has shown reliability and applicability in the clinical setting.https://www.mdpi.com/1420-3049/28/2/577[<sup>99m</sup>Tc]Tc-PSMA-I&Sautomated preparationtechnetium-99m |
| spellingShingle | Elisabeth Plhak Christopher Pichler Edith Gößnitzer Reingard M. Aigner Herbert Kvaternik Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S Molecules [<sup>99m</sup>Tc]Tc-PSMA-I&S automated preparation technetium-99m |
| title | Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S |
| title_full | Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S |
| title_fullStr | Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S |
| title_full_unstemmed | Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S |
| title_short | Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S |
| title_sort | development of in house synthesis and quality control of sup 99m sup tc tc psma i s |
| topic | [<sup>99m</sup>Tc]Tc-PSMA-I&S automated preparation technetium-99m |
| url | https://www.mdpi.com/1420-3049/28/2/577 |
| work_keys_str_mv | AT elisabethplhak developmentofinhousesynthesisandqualitycontrolofsup99msuptctcpsmais AT christopherpichler developmentofinhousesynthesisandqualitycontrolofsup99msuptctcpsmais AT edithgoßnitzer developmentofinhousesynthesisandqualitycontrolofsup99msuptctcpsmais AT reingardmaigner developmentofinhousesynthesisandqualitycontrolofsup99msuptctcpsmais AT herbertkvaternik developmentofinhousesynthesisandqualitycontrolofsup99msuptctcpsmais |